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Svelte Stent-on-a-Wire showed vascular healing and tissue response equivalent to that
observed with ML Vision stents.
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Scanning Electron Microscopic Observation of Coating Irregularities and Their
Precursors in Unexpanded Durable Polymer-Based Drug-Eluting Stents
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Grijpma2, Aart A van Apeldoorn2, Clemens von Birgelen1, 2
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Background: Previous scanning electron microscopy (SEM) studies in expanded DES
revealed differences in the frequency and size of coating irregularities between DES
types and specific distribution patterns, however, the origin of these irregularities is
unclear.The current study quantifies coating irregularities on unexpanded and expanded
durable polymer-based drug-eluting stents (DES) to gain insights into the potential
origin of coating irregularities.
Methods: We assessed at bench side a total of 1200 SEM images obtained in 30 DES
samples (15 expanded and 15 unexpanded) of Cypher Select, Taxus Liberté, Endeavor,
Xience V, and Resolute.
Results: For most types of coating irregularities seen on expanded DES (72%; 23/32),
a matching irregularity (n=18/24) and/or its precursor (n=11/24) was observed in
unexpanded corresponding DES. Only a few individual coating irregularities (13%;
4/32) could not be accessed in unexpanded samples, as these irregularities were located
on the (invisible) luminal side. Unexpanded Cypher Select showed (small) crater
lesions and cracks together with precursors of ‘peeling of polymer’. On unexpanded
Taxus Liberté, thinning of polymer, small bare metal areas, wrinkles and one type of
precursor was found. Unexpanded phosphorylcholine-based Endeavor stents showed
cracks, small bare metal areas, and crater lesions as well as precursors of the latter.
Unexpanded Xience V and Endeavor Resolute mainly revealed crater lesions and their
precursors.
Cypher Stent:Precursor of peelin (left); peeling (right)
Conclusion: SEM assessment demonstrated the presence of various coating
irregularities and/or their precursors on unexpanded durable polymer-based DES.
These findings provide evidence that coating irregularities arise during both DES
manufacturing and stent expansion.
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Background: The Polymeric Bioresorbable Myolimus-Eluting Scaffold is a novel drug
eluting device that combines a PLLA-based scaffold coated with a matrix of
bioresorbable polylactide and the drug Myolimus. Myolimus is a macrocyclic lactone
mTOR inhibitor similar to rapamycin (sirolimus) which has demonstrated potent anti-
proliferative properties in cell culture studies and successfully used in two First-in-Man
(FIM) studies on Elixir’s Myolimus eluting coronary stents. The drug dose is 3 mcg
per mm of scaffold length, similar to the dose used in the prior Elixir FIM studies.
Multiple radiopaque markers are located on each end of the scaffold to aid delivery
and placement in vivo. The objective of this study was to evaluate the safety and
efficacy of the Polymeric Bioresorbable Myolimus-Eluting Scaffold in a preclinical
model.
Methods: Polymeric Bioresorbable Myolimus-Eluting Scaffolds were implanted in
swine coronary arteries and evaluated over a period of 28, 90 and 180 days. Analyses
by OCT and histopathology were employed to evaluate the safety and efficacy of the
scaffolding systems. Pharmacokinetics (PK) of the drug from the scaffold was
measured using standard analytical techniques.
Results: The preclinical results of the Polymeric Bioresorbable Myolimus-Eluting
Scaffold implanted in the porcine coronary artery model are presented in the table
below. All vessels were patent after the evaluation period with histopathology profiles
expected for drug eluting stents. The PK analysis of the scaffold and tissue surrounding
the scaffold showed that approximately 80% of drug is released over a 28 day period.
Conclusion: The preclinical evaluation of the Polymeric Bioresorbable Myolimus-
Eluting Scaffold demonstrated safety and effectiveness in support of a First-in-Man
study.
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Background: Deficiency of the glutathione peroxidase-1 (GPx1) is associated with
in-stent stenosis (ISS).
Methods: We used a novel genome-wide gene expression network approach in human
atherectomy samples comparing atherosclerosis to ISS (n=89) to identify signaling
networks critical to the process of ISS. We found that a subnetwork with GPx1 as its
hub was among the most significantly differentially regulated (Fig 1, bar thickness
denotes association strength). We investigated the importance of Gpx1 in ISS using
knockout mice with constitutive deficiency of GPx1 crossed onto atherosclerotic ApoE-
KO background using a novel model of balloon angioplasty and stenting (BAS) in
mice.
Results: ApoE-KO mice had significantly decreased Gpx1 expression compared to
atherosclerosis. Despite equal stent expansion and injury scores, ISS was increased by
50% on histological cross-section (P<0.01) and 33% per-stented vessel longitudinally
by OCT (P<0.01) in GPx1/ApoE-KO mice 28 days following BAS (Fig 2, white arrows
denote neointima). In keeping with this, both proliferation (71%, P<0.01) and migration
(90%, P<0.01) were significantly increased in GPx1/ApoE-KO primary aortic smooth
muscle cells compared to ApoE-KO. In animals with additional targeted endothelial
reporter gene expression (Tie2-LacZ) we found Gpx1/ApoE-KO/LacZ mice had
significantly reduced endothelial coverage (58%, P=0.03) compared with ApoE-
KO/LacZ mice, suggesting impaired reendothelialization as a potential mechanism by
which Gpx1/ApoE-KO mice have increased ISS.
Conclusion: Using a network analysis approach we have identified an important role
for GPx1 signaling in vascular wall redox processes critical to ISS.
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Right through the Heart - Transseptal Access for Stent-Graft placement in the
Ascending Aorta
Sabine Helena Wipper, Christina Lohrenz, Klaas Peymann, Eike S Debus, Tilo
Kölbel
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Germany
Background: Transseptal access is routinely used for cardiological procedures in the
left heart, but not yet to access the aortic arch and its branches. Iliac and aortic
pathology such as obstruction and tortuosity may require antegrade access to advance
and deploy an endograft in the proximal parts of the thoracic aorta. The aim of the
present study was to test the feasibility of antegrade transseptal access to the ascending
aorta for stent-graft introduction and placement using a through-and-through guidewire
technique in a porcine model.
Methods: Transseptal puncture was performed in 6 domestic pigs (51-58kgBW) from
the inferior vena cava for guidewire-passage across the left heart to the descending
aorta to establish transseptal through-and-through access. Custom-made endografts
consisting of polyester-tube and two nitinol-stents (diameter 24mm, length of 32mm)
were advanced using the transvenous antegrade access and deployed under fluoroscopy
into the ascending aorta using a pull-and-push technique with moderate tension on the
wire. Hemodynamic monitoring (PiCCo catheter, Swan-Ganz catheter), transit-time
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